CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

NCT03328078 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

152

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Hematologic Malignancy
Refractory Hematologic Malignancy
Relapsed Primary Central Nervous System Lymphoma
Refractory Primary Central Nervous System Lymphoma

Interventions

DRUG: Emavusertib
DRUG: Ibrutinib

Sponsor

Curis, Inc.